Back to Search
Start Over
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
- Source :
- Nannizzi, S, Veal, G J, Giovannetti, E, Mey, V, Ricciardi, S, Ottley, C J, Tacca, M D & Danesi, R 2010, ' Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines ', Cancer Chemotherapy and Pharmacology, vol. 66, no. 3, pp. 547-558 . https://doi.org/10.1007/s00280-009-1195-2, Cancer Chemotherapy and Pharmacology, 66(3), 547-558. Springer Verlag, Cancer Chemotherapy and Pharmacology, Cancer chemotherapy and pharmacology, 2010, Vol.66(3), pp.547-558 [Peer Reviewed Journal]
- Publication Year :
- 2010
-
Abstract
- Purpose: Oxaliplatin effect in the treatment of colorectal cancer is improved upon combination with thymidylate synthase (TS) inhibitors. Pemetrexed is polyglutamated by the folylpolyglutamate synthase (FPGS) and blocks folate metabolism and DNA synthesis by inhibiting TS, dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT). The present study evaluates the pharmacological interaction between oxaliplatin and pemetrexed in colorectal cancer cells. Methods: Human HT29, WiDr, SW620 and LS174T cells were treated with oxaliplatin and pemetrexed. Drug interaction was studied using the combination index method, while cell cycle was investigated with flow cytometry. The effects of drugs on Akt phosphorylation and apoptosis were studied with ELISA and fluorescence microscopy, respectively. RT-PCR analysis was performed to assess whether drugs modulated the expression of pemetrexed targets and of genes involved in DNA repair (ERCC1 and ERCC2). Finally, platinum–DNA adduct levels were detected by ultra-sensitive multi-collector inductively coupled plasma mass spectrometry (ICP-MS). Results: A dose-dependent inhibition of cell growth was observed after drug exposure, while a synergistic interaction was detected preferentially with sequential combinations. Oxaliplatin enhanced cellular population in the S-phase. Drug combinations increased apoptotic indices with respect to single agents, and both drugs inhibited Akt phosphorylation. RT-PCR analysis showed a correlation between the FPGS/(TS × DHFR × GARFT) ratio and pemetrexed sensitivity, as well as a downregulation of ERCC1, ERCC2, TS, DHFR and GARFT after drug exposure. In addition, pretreatment with pemetrexed resulted in an increase of oxaliplatin–DNA adducts. Conclusion: These data demonstrate that oxaliplatin and pemetrexed synergistically interact against colon cancer cells, through modulation of cell cycle, inhibition of Akt phosphorylation, induction of apoptosis and modulation of gene expression.
- Subjects :
- Cancer Research
Organoplatinum Compounds
Colorectal cancer
Apoptosis
Toxicology
Thymidylate synthase
chemistry.chemical_compound
Glutamates
Dihydrofolate reductase
Antineoplastic Combined Chemotherapy Protocols
Pharmacology (medical)
Phosphorylation
biology
Reverse Transcriptase Polymerase Chain Reaction
Cell Cycle
Drug Synergism
Flow Cytometry
Colon cancer
Gene Expression Regulation, Neoplastic
Oxaliplatin
Pemetrexed
Biochemistry
Oncology
oxaliplatin
pemetrexed
colorectal cancer
Antifolate
Colonic Neoplasms
Original Article
DNA adducts
medicine.drug
Guanine
DNA repair
Enzyme-Linked Immunosorbent Assay
Cell Line, Tumor
medicine
Humans
Pharmacology
Dose-Response Relationship, Drug
Folylpolyglutamate synthase
Cancer
medicine.disease
chemistry
Microscopy, Fluorescence
biology.protein
Cancer research
Gene expression
Proto-Oncogene Proteins c-akt
Subjects
Details
- ISSN :
- 03445704
- Database :
- OpenAIRE
- Journal :
- Nannizzi, S, Veal, G J, Giovannetti, E, Mey, V, Ricciardi, S, Ottley, C J, Tacca, M D & Danesi, R 2010, ' Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines ', Cancer Chemotherapy and Pharmacology, vol. 66, no. 3, pp. 547-558 . https://doi.org/10.1007/s00280-009-1195-2, Cancer Chemotherapy and Pharmacology, 66(3), 547-558. Springer Verlag, Cancer Chemotherapy and Pharmacology, Cancer chemotherapy and pharmacology, 2010, Vol.66(3), pp.547-558 [Peer Reviewed Journal]
- Accession number :
- edsair.doi.dedup.....932cd4af3bea5c3d23fcb074144d6aa1